Life Sciences Tools and Services
Company Overview of CHDI Foundation, Inc.
CHDI Foundation, Inc., a not-for-profit research organization, engages in discovering and developing drugs that delay or slow the progression of Huntington's disease (HD). It supports and collaborates with a network of scientists in academic and industrial laboratories in the United States and internationally to discover drugs that slow the progression or delay the onset of HD. The company also provides financial support for research, as well as organizes workshops that bring scientists together to discuss ongoing programs, explore emerging questions, evaluate new technologies, and establish new partnerships and projects. In addition, it offers research tools and information to HD researcher...
6080 Center Drive
Los Angeles, CA 90045
Founded in 2003
Key Executives for CHDI Foundation, Inc.
Chief Administrative Officer
Compensation as of Fiscal Year 2014.
CHDI Foundation, Inc. Key Developments
Evotec AG and CHDI Foundation, Inc. Extends Collaboration to Find New Treatments for Huntington's Disease
Sep 18 14
Evotec AG has announced that CHDI Foundation, Inc. has extended and restated its collaboration with Evotec through 2017 to find new treatments for Huntington's disease. The collaboration-which aims to find new treatments for Huntington's disease, means that CHDI will fund up to 52 full-time scientists at Evotec over the next three years. The collaboration initially began in 2006 and has expanded considerably over this period to fully leverage Evotec's integrated neuroscience platform. The restated extension of this collaboration is a further validation of Evotec's broad drug discovery expertise in the field of neuroscience and includes an expansion to utilise Evotec's high-throughput screening and proteomics platforms. Evotec provides a full range of research activities and expertise in the neuroscience area to CHDI, including integrated biology and chemistry supported by compound and library management, target validation, stem cell research, high-content screening, computational chemistry, in vitro pharmacokinetics and protein production.
KineMed, Isis Pharmaceuticals, and CHDI Foundation Forge Huntington's Disease Therapeutic and Companion Biomarker Collaboration
Feb 21 13
KineMed, Inc., Isis Pharmaceuticals Inc. and CHDI Foundation, Inc. announced that they are collaborating to utilize KineMed's translational biomarker platform with Isis' antisense therapeutic program for Huntington's disease (HD). This collaboration, which builds on an earlier alliance between CHDI and KineMed to develop companion biomarkers of therapeutic response in HD, will provide Isis access to novel biomarkers for use in the development of an antisense drug to treat HD.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries